CD19 and acute lymphoblastic leukemia: A report on long-term follow-up of CD19 CAR T-cell therapy in patients with B-ALL (10) suggests that child and young adult patients have longer event-free median survival times than adults, implying that the difference may be attributed to age-related changes in the T cells collected from patients.